PitchSend

Investor Presentaiton

31st January 2024 We have a strong brand franchise in India Sales Contribution (IQVIA MAT Dec 2023) 65% Chronic Sales Pain 9% 12% NLEM Exposure 4 year CAGR (IQVIA MAT Mar 2020-2023) Cardiac Derma Focus on 50%+ 38% 20% 22% 4 1st to market products 19% 19% 16% specialty therapies Ophthal 31% 2,800+ MRS 250,000+ Doctors Covered 33% Ajanta Cardiac Ophthal Derma Pain 10 ajanta

View entire presentation